Human essential hypertension is a complex, multifactorial, quantitative trait under a polygenic control. Over the last decade several strategies have been used to dissect the genetic determinants of hypertension. Of these strategies, the study of rare monogenic forms of hypertension has been the most successful. Attempts to identify the multiple genes involved in the more common polygenic form of hypertension has been more difficult. Many laboratories use rat models of genetic hypertension where some of the complexity of studying human hypertension can be removed. Numerous crosses between hypertensive and normotensive strains have produced several quantitative trait loci (QTL) for blood pressure and other related phenotypes
Introduction
The multifactorial, polygenic nature and complex aetiology of essential hypertension has made the study of this disease difficult. Determining the genes involved in essential hypertension can be accomplished using several strategies such as firstly a candidate gene approach, where the choice of genes to be studied has been based on the knowledge of the pathophysiology of blood pressure regulation. [1] [2] [3] Secondly, by linkage analysis in families segregating for rare Mendelian forms of hypertension such as glucocorticoid remediable aldosteronism (GRA) [4] [5] [6] [7] [8] and thirdly by a genome-wide scanning approach, similar to those described and used in experimental models (see below for detailed description).
An alternative approach to studying hypertension, where at least some of the complexity in studying human subjects and families can be removed, is based on the cosegregation of phenotypes using experimental crosses derived from genetically hypertensive and control rat strains. Rat models of hypertension have been developed over many gener-such as left ventricular hypertrophy, stroke, insulin resistance and kidney failure. In this review we describe established and novel strategies to dissect the susceptibility and severity loci for human essential hypertension. We also illustrate a few successful examples of a direct translation of genetic discoveries from the experimental setting to human investigation. The use of new molecular tools such as gene 'chips' or microarrays for either gene expression profiling or single nucleotide polymorphisms (SNPs)-based total genome scanning strategies will ultimately result in new diagnostics and therapeutics for human essential hypertension.
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ations and their complete genetic homogeneity, large number of progeny, the ability to produce large genetic crosses and to provide tight control over environmental influences permit the dissection of complex traits such as hypertension. 9, 10 The aim of this review is to summarise our current knowledge and progress in the field of genetics of both experimental and human hypertension and to indicate how the application of the new strategies and discoveries achieved in the study of experimental models can be utilised to elucidate the multiple genes involved in the pathogenesis of essential hypertension in man.
Quantitative trait loci analysis in experimental models
Blood pressure in humans and animals is a quantitative trait under oligo-or polygenic control. It shows continuous variation from low to high blood pressure in a given population and, therefore, genetic determinants of blood pressure regulation can be studied by mapping quantitative trait loci (QTLs). Phenotypes can be linked to QTLs using microsatellite markers or short tandem DNA repeats which are widely and evenly distributed in the genome and relatively easy to score. A QTL can be assessed using a logarithm of odds ratio (lod) with a score equal Journal of Human Hypertension or greater than 3 being traditionally considered as significant. A lod score of 3 corresponds to 1000:1 odds for linkage, meaning that a set of observed data is a 1000-fold more likely to arise under a specific hypothesis of linkage than under the null hypothesis of independent assortment. Lander and Krugylak 11 have proposed thresholds for suggestive and significant linkage for mapping loci underlying complex traits in humans and in animal models dependent on the mapping method, mode of inheritance and crossover rate.
Over the past 30 years, many genetic models of hypertension which include the spontaneously hypertensive rat (SHR), its close relative the strokeprone SHR (SHRSP), Dahl salt-sensitive (S) and Milan hypertensive rats (MHS) to name a few, have been developed and studied. [12] [13] [14] These models develop spontaneous hypertension which is relatively consistent, within the given strain, in the severity and age of onset of high blood pressure. In a classic QTL mapping experiment, two phenotypically contrasting strains (with high blood pressure and with either low or normal blood pressure) are crossed. In the resulting F 1 progeny all individuals have 50% of genetic material from either parent. These F 1 animals are then brother × sister mated and a F 2 cosegregating cohort is obtained. Phenotypically these animals represent the entire variance of blood pressure between the hypertensive and normotensive progenitor strains as illustrated in previous published papers and reviews. [15] [16] [17] High fidelity phenotypying of the F 2 cohort and large panels of polymorphic microsatellite markers providing a good coverage of the rat genome are required for QTL mapping. Over the last decade, several groups have reported multiple QTLs responsible for blood pressure regulation in various crosses of hypertensive and normotensive rat strains as summarised in Table 1 . 15, [18] [19] [20] [21] Two main points can be taken from these data, firstly, it is evident that BP QTLs are found on the majority of rat chromosomes. Secondly, there are 'overlapping' or reproducible BP QTLs, which are present in more than one of the rat crosses examined. 22, 23 These 'overlapping' QTLs have become candidate regions for human essential hypertension as discussed later in this review.
Quantitative trait loci influencing other cardiovascular phenotypes
More recently, a series of interesting quantitative trait loci influencing cardiac hypertrophy, stroke, insulin resistance and indices of renal dysfunction have also been described and summarised in Table  1. 16,45-47 Three different rat crosses have shown the existence of QTLs related to left ventricular hypertrophy. These QTLs were found on chromosomes 2, 13, 14 and 17 and are at least partially blood pressure independent. 46, 48 Rubattu et al 27 have identified three QTLs related to the susceptibility for stroke in the SHR × SHRSP Heidelberg cross (SHR Hd × SHRSP Hd ). These QTLs, termed STR1, STR2 and STR3, were mapped on chromosomes 1, 5 and 4 respectively. STR1 showed highly significant linkage to the occurrence of stroke and strongly affected the latency to stroke in a recessive inheritance model. In contrast, STR2 and STR3 appeared to have a protective effect in the SHRSP Hd as the SP/SP homozygotes had increased latency to spontaneous strokes, at least when the animals were placed on a high salt, low potassium and low protein diet. Recently, data from our group showed a highly significant stroke severity locus on rat chromosome 5 with a lod score of 16.6. This QTL accounts for 67% of the total phenotypic variance in an F 2 cohort generated from SHRSP Gla /WKY Gla cross and is blood pressure independent. 38 This study was the first to identify a QTL for the severity of ischaemic brain damage after occlusion of the middle cerebral artery (MCA) in the SHRSP.
Several metabolic defects such as insulin resistance, defective fatty acid metabolism, hypertriglyceridaemia and reduced high-density lipoprotein (HDL) cholesterol in the SHR have all been mapped to the same region on rat chromosome 4. 36, 49, 50 Aitman et al 51 have recently proposed that a single gene, Cd36 may be responsible for several if not all of these defects as discussed below.
Genetic factors involved in hypertension-induced renal disease have been studied by several groups. Using a backcross of Fawn hooded hypertensive rats (FHH) which develops chronic renal failure, Brown et al 28 have identified and localised two genes, Rf1 and Rf2 on rat chromosome 1. Rf1 explains 44% of the genetic variance in proteinuria and strongly affects other measures of renal function, but has no significant effect on blood pressure. The second locus, Rf2, has a strong and significant effect on one measure of renal impairment, plasma albumin level. The region containing the Rf2 locus also showed some linkage to blood pressure. Churchill et al 45 studied the possible use of organ specific genome transplants to map QTLs expressed in the kidney that determine the susceptibility to hypertension induced renal damage. Transferring of histocompatible kidneys from BN rats into SHR rats that harbour the major histocompatibility complex from BN rats showed that the kidneys of BN rats were more susceptible to hypertension induced renal damage. These experiments provided direct evidence to support the hypothesis that genetic factors can determine the progression of renal failure.
Congenic strategies to dissect blood pressure QTLs
The existence of a putative QTL for blood pressure cannot be proven using a linkage study in segregating populations alone, but has to be further corroborated by the generation of a congenic strain, where a chromosomal segment from a donor strain has been introgressed into a recipient strain. This segment is initially large (10-25 cM) but can be further reduced by carrying out additional crosses and looking for animals where recombination has occurred around the region of interest. Animals exhibiting a crossover event between two flanking markers and still exhibiting the desired phenotype confirm that the gene responsible lies within the two flanking markers. Once the region has been adequately nar- rowed down to a more manageable size (1-2 cM), a physical map can be constructed using yeast artificial chromosomes, bacterial artificial chromosomes and/or P1 derived artificial chromosomes, 52-54 genes can then be identified and analysed for mutations.
Several congenic strains confirming or refuting blood pressure QTLs have been published within the last few years. These experimental data are summarised in Table 2 . Several lessons have been learned from these studies. For example, early studies which used large chromosomal fragments around the Sa locus to produce their congenics, [55] [56] [57] [58] all confirmed that this region contributed to significant Journal of Human Hypertension blood pressure differences. However, more recent studies utilising congenic substrains where small fragments of the QTL were transferred, have excluded the Sa gene as a candidate in this region. 59, 60 Two congenic strains produced by Deng et al, 62 by introgressing regions of chromosome 2 from either Wistar-kyoto (WKY) or Milan normotensive (MNS) into the homologous regions of Dahl salt-sensitive rats resulted in the reduction of blood pressure and the ratio of heart weight to body weight in the congenic strain. The data from the two congenic strains generated in this study established the existence of a The recipient strain is cited first and the donor second. Dahl RR: Dahl salt-resistant; BN( Lx ): donor strain originally derived by introgressing the mutant Lx gene of the Polydactylous rat on to the normotensive Brown-Norway background. SHRSP.WKYGla2a represents the congenic which produced the greatest reduction in blood pressure after salt-loading from several constructed (2a-b). WKY.SHRSPGla2c represents the congenic which produced the greatest increase in baseline blood pressure from several constructed (2c-d). Dahl SS.MNS(10a) represents the congenic which produced the greatest blood pressure reduction from the several constructed (10a-d).* this blood pressure difference refers only to the epistatic interaction.
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blood pressure QTL on rat chromosome 2 previously reported by the same group. 29 The time for a congenic strain to be generated is typically 3 to 4 years (8-12 backcrosses are required to obtain a 99% homogenous genetic background) but can be drastically shortened by the repeated screening of microsatellite markers distributed throughout the entire genetic background, a strategy known as 'speed' congenics. This repeated screening by utilising a marker assisted protocol, allows for the selection of a male from each backcross with the least donor alleles remaining in the genetic background, thereby reducing the number of generations necessary to construct a congenic strain. 11, 75 The application of this 'speed' congenic strategy has been successful in producing 10 congenic mouse strains derived from nonobese diabetic or NZM2410 strains on the C5BL/6 strain. 76, 77 Recently, reciprocal 'speed' congenic strains have been generated in our laboratory to dissect a BP QTL on rat chromosome 2. 61 This study not only confirmed the existence of a blood pressure QTL on chromosome 2 but demonstrated, for the first time, that a speed congenic strategy is applicable to the genetic dissection of experimental hypertension in the rat.
Association and linkage studies in essential hypertension
The study of human essential hypertension can be carried out using two basic molecular genetic approaches, association and linkage analysis. 10, 15, 78 Both approaches require the detection of polymorphic markers such as bi-allelic restriction fragment length polymorphisms, and variable nucleotide tandem repeats. Association studies test whether a particular allele occurs at higher frequency among affected when compared to unaffected individuals and is generally restricted to a genomic region or a variant being tested. This approach is heavily dependent on matching affected with unaffected subjects, such that the genetic background between the two groups is similar. A positive association either suggests that a particular allele causes a disease phenotype or the allele genotype cosegregates with the trait causing mutation. Positive association can also arise as an artefact of population admixture, where any phenotype present at a higher frequency in an ethnic group will show positive association with any allele that also happens to be more common in that group. Moreover, the issue of gene-gene interaction has been postulated to have a major impact and has only recently been studied systematically. Niu et al, 79 using a cohort of 310 concordant affected sib-pairs of Chinese ethnicity, and highly informative microsatellite markers in the vicinity of the genes encoding angiotensinogen, renin, ␤-and ␥-subunits of the epithelial sodium channel, ␣-adducin and kallikrein were unable to show any contribution of these genes alone or in concert, to the pathogenesis of essential hypertension among Chinese. These results emphasise the role of ethnic differences for genetics of complex diseases. 80, 81 Genome-wide linkage studies for complex traits such as essential hypertension are problematic and require careful study design. Phenotypic traits for a polygenic disease aggregate in families but unlike monogenic diseases, they do not segregate in any clear Mendelian fashion. A positive result using a linkage approach which generally tests related individuals, will implicate a region of genomic DNA containing a large number of genes, of which the causative gene for a particular disease will still have to be identified. For a complex disorder of late onset such as essential hypertension, many inherent problems exist using a linkage approach. Firstly, it is unusual to have both parents and children of the affected individual available for study. Therefore, the construction of a multigenerational pedigree is difficult. Secondly, the mode of inheritance which is required for parametric linkage analysis is unknown. Consequently a non-parametric approach, such as sib-pair analysis, that does not require information on the mode of inheritance or penetrance has been used in many studies. 82, 83 As a result of multiple contributing genes, each with small to moderate effects, and environmental factors that have to be taken into account, careful study design in a genome-wide analyses is necessary. Generating much attention is the use of sibpairs with extreme phenotypes, a sampling design recognised as being substantially more powerful than a design that uses randomly ascertained sibs. Though the use of discordant sibs is a powerful tool, as shown by theoretical work and simulation, [84] [85] [86] [87] it is counterbalanced by the large screening effort that is required to identify them. Xu et al 88 carried out a genome scan in search of genes regulating blood pressure and used three sib-pair types (discordant, highly concordant and concordant siblings) from a Chinese population, to extract maximal information from their genotyping effort. No chromosomal region achieved 5% genome-wide significance, though analysis of either systolic blood pressure (SBP) or diastolic blood pressure (DBP) revealed several promising regions with maximal lod scores greater than 2. In a similar study, Kruskhal et al 89 used discordant sib-pairs to localise genes that affect interindividual SBP. The discordant approach identified several regions on chromosomes 2, 5, 6 and 15 with significant linkage and chromosomes 9, 16, 18, 20, 21 with suggestive linkage, that contribute to genetic differences in SBP. Further studies on large and well phenotyped sibling cohorts are necessary to confirm or refute these preliminary data.
Monogenic hypertension
Although it is widely accepted that blood pressure is a polygenic trait, it is recognised that a small proportion of familial forms of hypertension are inherited as single gene disorders. The monogenic syndromes identified thus far are caused by direct or indirect dysregulation of renal sodium handling as illustrated schematically in Figure 1 . The study of these disorders provides not only novel diagnostic tools and an opportunity for targeted therapeutic intervention, but may also give some insight into the pathogenesis of the common forms of hypertension.
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Glucocorticoid remediable aldosteronism (GRA)
GRA is an autosomal dominant trait with a clinical phenotype varying from severe early onset hypertension to a much milder blood pressure elevation and mild hypokalaemia. The sine qua non of patients with GRA is that the secretion of aldosterone is regulated by adrenocorticotrophic hormone (ACTH) rather than its usual secretagogue angiotensin II. It is characterised by moderate hypersecretion of aldosterone, suppressed plasma renin activity and rapid reversal of these abnormalities with glucocorticoids. 90 Elevated 18-oxocortisol is the most consistent biochemical marker of the condition. 91 The hypertension is of moderate severity and becomes apparent early, with young children having blood pressure greater than the 95th percentile for the age and becoming frankly hypertensive before the age of 20. Associated signs of hypertension are frequent with left ventricular hypertrophy and retinopathy. Some affected kindreds have history of early deaths from stroke in family members before the age of 40. 92 All patients with GRA have a mutation localised to a segment of human chromosome 8, containing aldosterone synthase and steroid 11␤-hydroxylase genes (CYP11B2 and CYP11B1). The high homology (93%) and proximity (45 kb apart) of CYP11B1 and CYP11B2 genes makes it possible for them to become misaligned during meiosis. When this occurs, crossing over between the misaligned genes creates two chromosomes, one of which carries one CYP11B gene (deletion) and the other carries three CYP11B genes. The middle gene of the latter chromosome is a chimera with the 5Ј and the 3Ј ends corresponding to CYP11B1 and CYP11B2, respectively. 93 In all kindreds analysed, the breakpoints (points of transition between CYP11B1 and CYP11B2) are located between intron 2 and exon 4. By virtue of the 5Ј regulatory element of the 11␤-hydroxylase gene, aldosterone synthase gene expression and enzymatic activity are brought under the control of ACTH. This results in ectopic secretion of aldosterone from the adrenal fasciculata and leads to increased salt and water reabsorption and rise in blood pressure. 93 Studies on cDNA expression in cultured cells showed that chimeric enzymes with amino termini from CYP11B1 and carboxyl termini from CYP11B2 have 18-oxidase activity only if at least the region encoded by exons 5-9 corresponds to CYP11B2. If the sequence of exon 5 instead correspond to CYP11B1, the enzyme has 11␤-hydroxylase but no 18-oxidase activity, 6 and there is no location of crossover that yields an enzyme with intermediate levels of 18-oxidase activity. This is entirely consistent with the observation that no breakpoints in GRA alleles occur after exon 4.
Many kindreds with GRA are of Anglo-Irish extraction. 93, 94 Subjects with a maternal inheritance of GRA have a significantly higher plasma aldosterone and blood pressure compared to those with paternal inheritance suggesting genetic imprinting, but it may also represent exposure of the foetus to elevated levels of maternal aldosterone which exacerbates the condition. 95 Moreover, the chromosomes carrying the chimeric genes tend to occur in association with specific polymorphism of the CYP11B genes. This suggests that one of these polymorphism is or is in linkage disequilibrium with a structural polymorphism that predisposes to unequal crossing over during meiosis. In approximately 40% of alleles in Caucasians, the intron 2 of CYP11B2 has a sequence almost identical to that of CYP11B1. This region could promote misalignment of chromosomal segments during meiosis and thus increase the risk of unequal crossing over. The chimeric genes causing GRA can be readily detected by Southern blotting or polymerase chain reaction (PCR) and this gives a test of 100% sensitivity and specificity. 96 Subjects with GRA show a wide range of blood pressure including normotension. Studies to date indicate that this is not related to environmental factors like sodium intake or differences in steroid levels, ruling out allelic variations as the cause of variations in clinical severity. Polymorphisms in the 5Ј flanking region of CYP11B2 have been documented but none have been shown to affect gene expression. The −344C/T polymorphism was extensively studied as a possible regulator of CYP11B2, thus influencing the development of hypertension. 97 Associations have been observed between the C allele and aldosterone levels and blood pressure [98] [99] [100] and also with increased left ventricular mass and diameter, increased response of left ventricular mass to increases in dietary salt and decreased baroreflex sensitivity suggesting that it may be an independent risk factor for cardiovascular morbidity.
Liddle's syndrome
Liddle syndrome is an autosomal dominant form of hypertension characterised by hypokalaemia and suppressed renin and aldosterone levels. The high blood pressure responds specifically to amiloride, indicative of an upregulation of the amiloride sensitive epithelial sodium channel (ENaC) activity.
ENaC is composed of three subunits (␣, ␤ and ␥), each containing a COOH-terminal PY motif (xPPxY). Mutations causing Liddle syndrome alter or delete the PY motifs of the ␤-or ␥-ENaC which is a conserved motif essential for channel internalisation. Most mutations reported to date result in the elimination of the last 45-76 normal amino acids from the C-terminus of the ␤-or ␥-subunits which lie adjacent on the short arm of chromosome 16. 4, 5, 101 The crucial role played by the PY motif in ␤-ENaC and ␥-ENaC has been highlighted by the identification of the two missense mutations P616L and Y618H in other Liddle syndrome patients. 102, 103 No Liddle syndrome mutations have so far been identified in ␣-ENaC.
The increased activity of the ENaC is not explained by alteration of single channel conductance but rather by an increased number of channels inserted into the plasma membrane. 104 Since
105,106
In a study of hypertensives of Afro-Carribean origin, the T594M sodium-channel ␤-subunit mutation was found to occur more frequently in people with hypertension than those without. 107 To test the hypothesis that minor mutations of the gene may be responsible for some subtypes of low-renin essential hypertension, the last exon of the ␤-ENaC subunit gene was analysed in a series of 525 subjects of Caucasian and Afro-Caribbean origin. Seven amino acid changes were detected with variants being more common in those of African origin. However, expression studies of these variants in Xenopus oocytes did not show any significant functional effects.
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Syndrome of apparent mineralocorticoid excess (AME) AME is an autosomal recessive disorder causing preand post-natal growth failure, juvenile hypertension, hypokalaemic metabolic alkalosis and hyporeninaemic hypoaldosteronism. A low salt diet or blockade of mineralocorticoid receptors with spironolactone ameliorates the hypertension, whereas ACTH and hydrocortisone exacerbate it. 109 Levels of all known mineralocorticoids are low. Cortisol halflife in plasma is increased along with the ratios of cortisol to cortisone and of 5-␣-to 5-␤-cortisol metabolites in the serum and urine. An elevated ratio of cortisol to cortisone metabolites in the urine (tetrahydrocortisol plus allotetrahydrocortisol to tetrahydrocortisone [(THF+aTHF)/THE]) is considered pathognomic for this disorder. This suggests that cortisol acts as a stronger mineralocorticoid than is normally the case. 110 The defect in AME is a deficiency of 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2) enzyme activity. Both aldosterone and cortisol in vitro are potent activators of the mineralocorticoid receptor in contrast to the situation in vivo where aldosterone is a vastly more potent activator of the renal mineralocorticoid receptor. Cells that respond selectively to mineralocorticoids contain the enzyme 11␤-hydroxysteroid dehydrogenase that metabolises cortisol to cortisone, a steroid that is incapable of activating the Journal of Human Hypertension mineralocorticoid receptor. This mechanism protects the mineralocorticoid receptor from cortisol, resulting in selective activation by aldosterone. 105 The active component of liquorice, glycyrrhetinic acid inhibits 11␤-HSD in isolated rat kidney microsomes and the similar abnormality occurring with liquorice intoxication in humans is a reversible pharmacological counterpart to the syndrome of apparent mineralocorticoid excess. 111 There are two distinct isoenzymes of the 11␤-HSD. The liver or type 1 isozyme has a relatively low affinity for steroids and is expressed at high levels in the liver but poorly in the kidney and is not defective in AME. The kidney or the type 2 isozyme has high steroid affinity and is expressed at high levels in the kidney and placenta.
Thus far 18 different mutations in the 11␤-HSD2 gene have been published involving 21 kindreds with AME. There is significant correlation between the degree of enzymatic impairment and biochemical severity as measured by ratio of cortisol to cortisone metabolites. 112 While apparent 11␤-HSD2 deficiency causes hypertension, it is reasonable to hypothesise that milder decreases in enzymatic activity might be associated with the common essential hypertension. In rats placental 11␤-HSD activity is inversely correlated with placental weight and directly correlated with term foetal weight. Patients with AME are often born with mild to moderate intrauterine growth retardation. It is likely that low levels of 11␤-HSD in the placenta permit excessive quantities of maternal glucocorticoids to cross the placenta and inhibit foetal growth. In retrospective human population studies, low birth weight and increased placental weight are increased risk factors for subsequent development of hypertension. Although variations in 11␤-HSD might in principle be responsible for this correlation, studies in humans have not found a relation between 11␤-HSD activity and birth weight. 
Gordon's syndrome
Pseudohypoaldosteronism type II, also known as familial hyperkalaemia and hypertension or Gordon's syndrome, is characterised by hyperkalaemia despite normal renal glomerular filtration, hypertension and correction of physiologic abnormalities by thiazide diuretics. The blood pressure level is not high, and the phenotype appears attenuated, with fluctuating hyperkalaemia and hyperchloraemic acidosis. The response of hyperkalaemia to dietary salt restriction and to mineralocorticoids is variable, suggesting genetic heterogeneity. Analysis of PHA II families showing autosomal dominant transmission revealed linkage of PHA II to chromosomes 1q31-q42 and 17p11-q21. 114, 115 This is a form of hypertension which most closely mimics essential hypertension and the mild phenotype may leave a large proportion of patients with Gordon's syndrome undiagnosed.
Autosomal dominant hypertension with brachydactyly
A unique Turkish kindred was described in 1973 with autosomal dominant brachydactyly and severe hypertension where the two traits cosegregated completely. This syndrome has been mapped to a 4 cM region of chromosome 12p. 116, 117 A similar syndrome has been described in a family in Canada and another in the US. 118 The importance of this syndrome to primary hypertension is speculative. A putative mechanism in these families is the presence of a vascular anomaly involving the posterior inferior cerebellar artery at the ventrolateral medulla which was present in all 15 affected subjects examined and absent in all of the 11 non-affected siblings. 119 No detailed neurophysiological studies have been done in subjects with this syndrome and hence one is not sure whether this form of hypertension has a neurovascular basis. However a direct causal relationship has been shown between raised blood pressure and neurovascular compression of the ventrolateral medulla in humans with surgical decompression resulting in a decline in blood pressure. 120 
Candidate genes in hypertension
Although considerable progress has been made in unravelling the molecular genetics of some rare monogenic forms of hypertension as illustrated above, it remains extremely difficult to identify the genes responsible for essential hypertension. The study of candidate genes, which assumes that a given gene or a group of genes involved in a specific function might contribute to blood pressure variation, has resulted in conflicting results despite an exponential increase in the number of studies trying to implicate these genes. A schematic representation of chosen candidate genes and the potential role of their functional variants is illustrated in Figure 1 .
Angiotensinogen
The renin-angiotensin system (RAS) regulates blood pressure and sodium balance. Angiotensinogen is a key component of this system. The candidacy of angiotensinogen for a role in the genetic basis of hypertension is supported by the observation that plasma angiotensinogen levels track with raised blood pressure through families. 121 Transgenic mice with overexpression of a rat angiotensinogen gene develop hypertension and knockout mice with a disrupted gene and absent angiotensinogen production develop low blood pressure. 122 The potential role of the AGT gene in human essential hypertension has been tested using a highly polymorphic dinucleotide GT repeat displaying 10 alleles and located in the 3Ј region of the angiotensinogen gene. 123 When a total of 379 hypertensive sib-pairs were studied for the AGT gene, a 17% excess of allele sharing was found when the sib-pairs were stratified according to the severity of hypertension. 121 Significant linkage was found in the male pairs while no excess of shared angiotensinogen alleles was observed in female-female comparisons, suggesting the influence of an epistatic hormonal phenomenon. From this study, it was estimated that mutations at the AGT locus might be a predisposing factor in at least 3-6% of hypertensives younger than 60 years of age. 121 Subsequently a large European study involving 630 sib-pairs found no evidence of linkage. 124 Also no evidence of linkage was found in sib-pairs studies in Chinese and Afro-Caribbeans. 80 Several missense mutations have been found, mainly located on exon 2 of the AGT gene. Most of them were rare and detected in a few hypertensive probands. Two polymorphisms T174M and M235T were found to be in complete linkage disequilibrium. The M235T polymorphism, which showed an association with hypertension and plasma angiotensinogen, was studied in many case-control studies. The frequency of the AGT T235 allele varies strongly with ethnic groups, being the predominant allele in the African population (0.90-0.95) and more frequent in the Asians (0.75) than in the Caucasians (0.40). In a meta-analysis of all relevant articles published between 1992 and 1996, involving 5493 Caucasian patients, the AGT T235 allele was significantly associated with hypertension in subjects with a positive family history of hypertension and in those with more severe hypertension. 128 A positive association of the T235 allele with hypertension was found in the Japanese, and native adult Canadians. 129, 130 The T174M polymorphism did not show any linkage with hypertension in most case control studies.
A G-A substitution at position 6 upstream of the initial transcription site was found to be in linkage disequilibrium with the T235 allele and haplotypes containing both the G-6A and M235T polymorphism were associated with hypertension. 131 There is no evidence that T235 allele directly affects the function, secretion or metabolism of angiotensinogen. The other hypothesis is that this variant could serve as a marker for unknown molecular variants directly mediating predisposition to essential hypertension.
Angiotensin-1 converting enzyme gene
Angiotensin-converting enzyme (ACE) has a key role in angiotensin II generation and bradykinin degradation, and through them affects vascular wall reactivity and morphology and kidney function. Moreover, the ACE gene lies within the genomic region which is linked with hypertension in the SHRSP strain of rat. The human ACE gene has been cloned and localised to chromosome 17q23 and a 287bp insertion/deletion (I/D) polymorphism in intron 16 has been identified and used extensively as a genetic marker. The polymorphism of the ACE gene strongly modulates plasma ACE level. Therefore any relationship found with the ACE gene marker might be attributable to the phenotype associated with the polymorphism.
Two studies have reported a linkage of the ACE locus with diastolic blood pressure or mean blood pressure. In a sample consisting of 3095 participants of the Framingham Heart Study, there was an association of the ACE DD genotype with increased diastolic blood pressure in men but not in women. 132 In a large population-based sample of 1488 siblings the ACE locus was found to be linked to diastolic blood pressure and mean blood pressure in adolescents, at a mean age of 15 years. 133 The DD genotype is also associated with a higher risk for cardiovascular disease, particularly acute myocardial infarction, left ventricular and carotid wall hypertrophy, restenosis after transluminal coronary artery angioplasty and reduction in LV mass index in response to enalapril but not associated with stroke. 118, [134] [135] [136] Multiple variants that are in linkage disequilibrium with the I/D polymorphism have been described 137 but it is unknown whether any of these are implicated alone or in combination in the determination of plasma ACE levels. A combined cladistic/measured haplotype analysis of 10 polymorphisms spanning 26 kb of the ACE gene excluded upstream sequences including the ACE promoter from harbouring the major ACE-linked variant involved in 36% of total trait variability.
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Angiotensin type I receptor
There is little data concerning the biology of AT1R in hypertension, as it is a cellular component of the RAS and thus less accessible to quantitative measurement.
Though polymorphisms have been found in the coding region and in the 3Ј untranslated region, only one polymorphism 1166C of the A1166C polymorphism was more frequent in hypertensives. No evidence for linkage was found in a sib-pair study involving 267 pairs from 138 pedigrees, using a dinucleotide microsatellite marker. 139 Either the association found with the A1166C polymorphism is spurious or the sib-pair study is not sensitive enough to detect the linkage, due to its lower power compared to the association study. Another study performed in Australian subjects found a positive association with the A1166C polymorphism, but it was not the case in German hypertensives. 140, 141 Analysing the A1166C polymorphism jointly with the ACE D/I polymorphism, showed that the increased risk of MI associated with the DD genotype was restricted to subjects bearing the 1166C allele either in the heterozygous or homozygous state. 142 Since no alteration in the coding region of the gene has been detected in hypertensives, the next step would be to look for polymorphisms in the regulatory regions of the gene resulting in modification of receptor number rather than receptor affinity.
Endothelial nitric oxide synthase gene
Several lines of evidence suggest that blood pressure levels result from an equilibrium between a vasoconstrictor tone (mainly renin-angiotensin and endothelin systems), and a vasodilator tone, due to nitric oxide, prostacyclin and other less characterised factors, such as endothelium derived hyperpolarising factor (EDHF).
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The nitric oxide synthases are a family of complex enzymes that catalyse the five-electron oxidation of L-arginine to form NO and L-citrulline. The endothelial isoform of NO synthase (eNOS), represents a major candidate gene since this isoform is responsible for the constitutive regeneration of NO from arginine by the endothelial cells. No polymorphisms have been detected in the coding region of the of the human eNOS gene. 143 Using a highly informative dinucleotide repeat inside intron 13, two sib-pair studies showed no significant excess of allele sharing in siblings. 144 These two studies do not support a prominent role of the eNOS gene in essential hypertension and suggest that the NO-related endothelial dysfunction is probably secondary to high blood pressure.
Endothelin system genes
Endothelins (ETs) are 21-amino-acid peptides produced in many cells and tissues. The vascular ET system is represented mainly by ET-1 produced in endothelial cells and is cleaved from a larger precursor, 38 amino acids in length, by the endothelin converting enzyme (ECE). 145 It binds to the ET A receptor on the vascular smooth muscle and provokes vasoconstriction. Studies with endothelin receptor antagonists have indicated that endothelin-1 probably has complex opposing vascular effects mediated through vascular smooth muscle and endothelial ET(A) and ET(B) receptors. Endogenous generation of endothelin-1 appears to contribute to maintenance of basal vascular tone and blood pressure through activation of vascular smooth muscle ET(A) receptors. 146 At the same time, endogenous endothelin-1 acts through endothelial ET(B) receptors to stimulate formation of nitric oxide tonically and to oppose vasoconstriction. 145 In addition to its direct vascular effects, endothelin-1 has inotropic and mitogenic properties, influences homeostasis of salt and water, alters central and peripheral sympathetic activity and stimulates the renin-angiotensin-aldosterone system. In view of the multiple cardiovascular actions of endothelin-1, there has been much interest in its contribution to the pathophysiology of hypertension.
Polymorphisms of the ET-1 and ET(A) receptor genes have shown non-significant or marginally significant associations with hypertension. 147 It is worth noting that the ECE gene is located on chromosome 1p36 on which a locus for systolic blood pressure was found by sib-pair analysis with a protein marker namely 6-phosphogluconate dehydrogenase.
148
Genes of the signal transduction pathways
G-proteins were considered to be involved in primary hypertension when pertussis toxin-sensitive G proteins in lymphoblasts and fibroblasts from selected patients with essential hypertension were found to be engaged in enhanced signal transduction. An increase in Na-H exchange was observed in immortalised lymphoblasts from hypertensives, and this was assumed to be due to increased intracellular transduction as the lymphoblasts showed increased cell activation restricted to the receptors coupled with the pertussis toxin-sensitive G-proteins. A splice variant of the G-protein subunit-␤3 (GNB3) consisting of an inframe deletion of 123 base pairs in exon 9 was found in subjects bearing at least one T allele of a C825T polymorphism of the GNB3 gene resulting in the loss of 41 amino acids and one WD repeat domain of the ␤-subunit of the G-protein. 149 It is not known whether the C825T polymorphism is in complete linkage disequilibrium with another functional polymorphism responsible for the splice variant, or if the T allele is causative. While some studies have shown a consistent linkage of the polymorphism with hypertension, [150] [151] [152] other studies have not shown any association. 153, 154 Genotyping 5254 individuals from 55 native population samples showed the highest 825T allele frequencies in black Africans (82%) and intermediate values in East Asians (47%). The 825T allele was significantly associated with obesity in three groups of young Germans, Chinese and black South Africans with low, intermediate and high 825T allele frequencies respectively. 155 Also the 825T allele was associated with impaired LV diastolic filling in mild to moderate hypertensives who did not show any differences in blood pressure, left ventricular (LV) structure and function when stratified according to ACE I/D or AT1R A1166C polymorphisms.
156
Adducin
Genetic hypertension in the Milan hypertensive (MHS) rats is due to a renal abnormality in the ability to excrete salt. 157 This alteration is genetically determined, since hypertension can be transplanted with MHS kidney to Milan normotensive (MNS) rats, even when the kidney is derived from a young prehypertensive rat. 158 Na/H countertransport in the brush-border vesicles, Na-K co-transport in the luminal membrane of the thick ascending limb, and the activity and mRNA expression of the basolateral Na-K ATPase both in the proximal and ascending limb tubules are all increased in MHS as compared with MNS. Since these differences in ion transport disappear after removal of cytoskeleton, cross-immunisation studies set up to detect possible differences between the cytoskeletal components of the two strains revealed a difference in a protein subsequently identified as adducin. 158 Adducin is an ␣/␤ heterodimeric protein which participates in the assembly of spectrin-actin cytoskeleton, modulates the actin polymerization, binds calmodulin, is phosphorylated by PKC and tyrosine kinase and regulates cell signal transduction. Point mutations in both the ␣-and ␤-adducin subunits account for around 50% of the difference in blood pressure between MHS and MNS strains. 159 Transfection of hypertensive and normotensive ␣-adducin variants to rat kidney cells showed that the former increases the surface expression and maximal rate of Na-K pump. 160 A direct and specific interaction between adducin and Na-K ATPase suggests the possibility of such an interaction in intact renal membranes. 161 This finding provides therefore the molecular basis for a constitutive increase in tubular sodium reabsorption in MHS rats. The cellular and biochemical alteration caused by adducin polymorphism in MHS rats are also associated with an increased production of an endogenous Na-K pump inhibitor, the so called ouabain-like factor, which is involved in the Na-K pump modulation and consequently in cell ion handling.
There is a close homology (94%) for the ␣-adducin gene between rat and man. A functional mutation in the ␣-adducin gene (Gly460Trp) has been found to be associated with human essential hypertension in some studies, 162, 163 while others have failed to find an association. 164 However the blood pressure fall after a diuretic in patients carrying the 460Trp variant was greater than that of patients with 460Gly, and thus adducin polymorphism may be used to identify patients with a salt sensitive form of hypertension. 165 In a study of more than 400 hypertensives from Milan and Sassari, the ␣-adducin 460Trp allele was found to be more frequent among the hypertensives of Milan and not Sassari. 166 Basal plasma renin was lower and blood pressure fall after diuretic was significantly more pronounced in hypertensives carrying at least one 460Trp allele irrespective of their membership in the Milan or Sassari cohort. One possible explanation for this finding could be the presence of an independently inherited allele counteracting the effect of ␣-adducin.
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Comparative analysis between man and rat
The considerable progress made in localising genes in both man and mouse and the development of finer more detailed maps of the rat genome has made it possible to perform comparative genome-wide analyses between these three species and to identify regions of conserved synteny. [167] [168] [169] [170] [171] Recently, the development of new resources for genome studies in the rat, such as yeast and bacterial large-insert clone libraries, the construction of a robust framework map including over 4500 microsatellite markers and the development of a genome-wide comparative map between rat, mouse and man (http://www.otsuka.genome.ad.jp) should make comparative analyses easier. [172] [173] [174] [175] As an alternative to investigating rare forms of hypertension and/or using the candidate gene approach, linkage studies in hereditary hypertension in the rat have led to the detection of several loci involved in blood pressure regulation as mentioned previously. Regions of homology between blood pressure related QTLs in rat and man represent candidate regions for containing susceptibility genes for hypertension. Several studies have shown that a BP QTL containing the ACE gene on rat chromosome 10 exists in several crosses of normotensive and hypertensive rat strains. Based on the comparative mapping data between rat, mouse and man available at the time, Julier et al 176 hypothesised that there might be a susceptibility gene(s) on the long arm of human chromosome 17. They carried out linkage analyses on a panel of 357 French and UK families containing a 384 sibships with one or more hypertensive offspring and a total of 21 microsatellite markers covering 110 cM, a higher density of markers was selected in the region near the ACE locus. Four statistical methods using parametric and non-parametric genetic models were used to analyse data and a significant linkage was established with two microsatellite markers that reside 18 cM proximal to the ACE locus. Other candidate genes such as phenylethanolamine-Nmethyltransferase, nerve growth factor receptor and pseudohypoaldosteronism type II B locus have been mapped to the interval. In a similar study by Baima et al, 177 a series of microsatellite markers that span 12 cM near the locus found by Julier et al 176 and one marker close to the ACE locus were studied in a collection of white and black sib-pairs in the United States. Two adjacent markers on chromosome 17 within this set of markers showed linkage with essential hypertension, but only in the white sibs. Further linkage studies will have to be carried out to provide additional support for a gene involved in blood pressure regulation at this location.
In addition to the BP-related QTL found on rat chromosome 10, a large number of studies suggest that a BP-related QTL exist on rat chromosome 2, suggesting that homologous regions in the human genome should contain susceptibility genes for hypertension. Rapp et al 74 showed that there was an epistatic interaction between these two rat QTLs and suggested that future human studies should look for an interaction between the human chromosomal regions homologous to rat chromosome 2 and 10 congenic segments.
Large amounts of data are being generated by genome projects, some of which are in the form of expressed sequence tags (ESTs). [178] [179] [180] This has led to the construction of comparative databases such as XREFdb and dbEST and has provided valuable comparative insights into gene structure and expression. As more ESTs are discovered and mapped, the ability to assess the patterns of expression of an ever-growing list of candidate genes in a chromosomal region associated with a disease both at the RNA and protein level will become more informative and determine the course of future investigation.
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New technologies (gene expression profiling and cDNA microarrays)
Genetic studies of complex diseases such as hypertension are becoming more sophisticated due to the use of cDNA microarrays for expression profiling of thousands of genes in a single experiment. 51, 185 cDNA arrays used for gene expression are based on the ability of being able to immobilise nucleic acids on an inert matrix such as a glass microscope slide and then total ribonucleic acid (RNA) from a test and reference sample, labelled with fluorescent dyes using a round of reverse transcription, are allowed to hybridise to the bound nucleic acid. Levels of gene expression of the test sample relative to the reference sample can then be measured using a scanJournal of Human Hypertension ning confocal laser microscope. 186 Aitman et al 51 were first to utilise this for cardiovascular genetics. They combined the use of cDNA microarrays, congenic mapping and radiation hybrid mapping to identify the insulin resistance gene, Cd36 on rat chromosome 4, which is responsible for defective fatty acid and glucose metabolism in the SHR. Furthermore, they constructed a congenic strain, SHR 4, by transferring a 37 cM chromosomal segment from BN to SHR. This congenic strain had lower blood pressure, and ameliorated dietary induced glucose intolerance, hyperinsulinaemia and hypertriglyceridaemia when compared to its SHR progenitor. [49] [50] [51] For the expression profiling experiments described by Aitman et al, 51 cDNA microarrays arrays were fabricated using 10 000 cDNA clones randomly collected from a normalised cDNA library prepared from the left ventricles of male SpragueDawley rats. Fluorescently labelled cDNA probes were then generated from the reverse transcription of poly (A) + mRNA extracted from the epididymal fat of SHR, BN and the congenic strain SHR 4. Competitive hybridisation of the fluorescently labelled probes, in a pair-wise fashion, was then carried out on the cDNA microarray. Gene expression profiling using the cDNA microarray demonstrated that there was a Cd36 deficiency in SHR. A number of other genes also showed differential hybridisation on the microarray, and some may lie on the Cd36 metabolic pathway. 51 Microarray technologies can also be used to scan the entire genome for disease polymorphisms, using small amounts of biological material and do so at the nucleotide level with very high accuracy. Recent studies have shown that single nucleotide polymorphisms (SNPs) are very abundant in the human genome, occurring at a density of 1 per kilobase of DNA and new strategies have been developed to detect them. 187, 188 It has been estimated that a collection of 1000 biallelic SNPs would have the same power as 400 microsatellite markers. 189 Using this technology we can catalogue common sequence variants in both coding and regulatory regions of human genes and test these directly for association with a disease phenotype. Moreover, the same technology could be used to generate a genome-wide high resolution map of known SNPs to scan the genome for marker disease associations. 190, 191 A number of points have been raised in a review by Chakravarti on the limitations of using SNPs for gene mapping of complex traits, 192 however, there is little doubt that these will soon be resolved and microarray technology will have a major role in dissecting the genes involved in hypertension and other polygenic disorders.
Pharmacogenomics
It is evident that variation between patients at the molecular level of a target/protein pathway can affect an individual's response to treatment by affecting the uptake, activation, metabolism, excretion and activity of the drug. The observation that a given drug may statistically have an action in the general population, but in an individual the protein target or drug may not be relevant, have led
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to a new field of study called pharmacogenomics. 193 Pharmacogenomics may be applied by using polymorphic markers of appropriate candidate genes to identify the genetic characteristics of responders to both known and novel antihypertensive drugs. Genetic polymorphisms may also be applied to screen individuals to predict adverse effects from a specific treatment.
There are some early examples of these new strategies for both experimental and human hypertension. A backcross population derived from a cross of Lyon hypertensive rats with Lyon normotensive rats, has recently shown the presence of a locus on chromosome 2 that cosegregates with the response to PY10008-068, the dihydropyridine calcium antagonist. This suggests that genetic factors may indeed influence the response to antihypertensive drugs. 194 Studies in human hypertension showed that the ␣-adducin polymorphism can predict the response to thiazide diuretics. 165 Moreover, Hirnogorani et al 195 found that angiotensinogen variants were associated with the magnitude of decrease in blood pressure after ACE inhibition. However, a study by Dudley et al, 196 concluded that the variability between individuals with essential hypertension, in blood pressure response, to a large number of antihypertensive drugs could not be attributed to the AGT M235T and ACE I/D polymorphisms.
Conclusions
In summary, this review has discussed the current progress and strategies in the identification genes involved in the pathogeneisis of hypertension using both experimental models and human approaches (association and linkage studies). As the field of research develops and matures, it has become more evident that the many approaches used in studying hypertension, are in fact complementary and not solely exclusive/independent of each other. The further dissection of the genes involved in essential hypertension will be dependent on novel approaches in terms of study design, analyses, populations and new technologies such as cDNA microarrays. All these developments will ultimately result in the improved diagnosis, prognosis and treatment of hypertension.
